deepDTnet repurposes topotecan as an RORγt inhibitor for multiple-sclerosis models
The deep-learning network deepDTnet predicted retinoic-acid-receptor-related orphan receptor gamma-t (RORγt) as a previously unrecognized target of topotecan. Biochemical assays showed direct inhibition (IC50 0.43 μM), and topotecan improved outcomes in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis.
Technology: deepDTnet, heterogeneous drug–gene–disease network embedding with deep learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Biochemical assays showed direct inhibition (IC50 0.43 μM), and topotecan improved outcomes in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis.
- Still unknown: Evidence is preclinical: direct target and mouse-model assays do not establish safety or effectiveness in people with multiple sclerosis. Topotecan is an established anticancer drug, and its new target/indication remains a repurposing hypothesis.
- AI role: The model integrated 15 types of chemical, genomic, phenotypic and cellular network profiles to rank new drug targets. It nominated RORγt for topotecan, which the team tested using direct binding/transcriptional assays and a mouse EAE disease model.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/34123272/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 366 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.